


**Figure S1** Validation of the angiogenesis-related lncRNA signature. (A-D) Validation of the angiogenesis-related lncRNA signature in the external validation set. AUC, area under the curve; lncRNAs, long noncoding RNAs; ROC, receiver operating characteristic.



**Figure S2** The relationship between the lncRNA signature and the immune microenvironment of GBM. (A-C) The results analyzed in the “immunedeconv” package showed significant differences in macrophage M2, uncharacterized cells, and macrophage/monocyte cells between the high- and low-risk groups (P<0.05). (D) Online database xCell analysis showed the difference in immune/nonimmune cells between the high- and low-risk groups (P<0.05). (E) The leukocyte fraction was significantly higher in the high-risk group than in the low-risk group (P<0.05). \*, P<0.05; \*\*, P<0.01. aDC, activated DCs; CLP, common lymphoid progenitor; CMP, common myeloid progenitors; cDC, conventional dendritic cell; DC, dendritic cell; GBM, glioblastoma multiforme; GMP, granulocyte-monocyte progenitor; HSC, hepatic stellate cell; iDC, immature dendritic cells; lncRNAs, long noncoding RNAs; ly, lymphatic; MEP, megakaryocyte erythroid progenitor; MPP, multipotent blood progenitors; MSC, mesenchymal stem cell; mv, microvascular; NK, natural killer; NKT, natural killer T; ns, no significance; pDC, plasmacytoid dendritic cell; Tcm, central memory T cell; Tem, effector memory T cell; Tgd,  $\gamma/\delta$  T cell; Treg, T regulator cell.



